Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19.

作者: Andrea Ferreira Haddad , Eduardo Costa , Pedro Pimenta de Mello Spineti , Armando Leão Ferreira Neto , André Filipe Marcondes Vieira

DOI: 10.1016/J.BJID.2021.101549

关键词:

摘要: Abstract Objectives To assess the efficacy of hydroxychloroquine in combination with azithromycin terms clinical and biochemical outcomes adult patients COVID-19 hospitalized for acute respiratory distress syndrome (ARDS), to describe occurrence adverse events. Method Retrospective comparative study, based a quaternary private hospital Rio de Janeiro, Brazil, involving 193 mild moderate related ARSD, analyzing treatment on outcomes. Results The active group comprised 101 (52.3%) using associated control 92 (47.7%) who did not take these medications. Median age was 59 (47–70) 65 (47−77) (p   0.05). No difference mortality, duration non-invasive oxygen use or hospitalization seen between groups. therapeutic regimen well tolerated, only eight (7.9%) presenting gastrointestinal symptoms withdrawn due QTc prolongation. Conclusions Patients treated combined had similar This considered ineffective ARDS few non-severe

参考文章(25)
Adrea Savarino, John R Boelaert, Antonio Cassone, Giancario Majori, Roberto Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases Lancet Infectious Diseases. ,vol. 3, pp. 722- 727 ,(2003) , 10.1016/S1473-3099(03)00806-5
Eva Schrezenmeier, Thomas Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Reviews Rheumatology. ,vol. 16, pp. 155- 166 ,(2020) , 10.1038/S41584-020-0372-X
Manli Wang, Ruiyuan Cao, Leike Zhang, Xinglou Yang, Jia Liu, Mingyue Xu, Zhengli Shi, Zhihong Hu, Wu Zhong, Gengfu Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. ,vol. 30, pp. 269- 271 ,(2020) , 10.1038/S41422-020-0282-0
Wei-jie Guan, Zheng-yi Ni, Yu Hu, Wen-hua Liang, Chun-quan Ou, Jian-xing He, Lei Liu, Hong Shan, Chun-liang Lei, David S.C. Hui, Bin Du, Lan-juan Li, Guang Zeng, Kwok-Yung Yuen, Ru-chong Chen, Chun-li Tang, Tao Wang, Ping-yan Chen, Jie Xiang, Shi-yue Li, Jin-lin Wang, Zi-jing Liang, Yi-xiang Peng, Li Wei, Yong Liu, Ya-hua Hu, Peng Peng, Jian-ming Wang, Ji-yang Liu, Zhong Chen, Gang Li, Zhi-jian Zheng, Shao-qin Qiu, Jie Luo, Chang-jiang Ye, Shao-yong Zhu, Nan-shan Zhong, Clinical Characteristics of Coronavirus Disease 2019 in China The New England Journal of Medicine. ,vol. 382, pp. 1708- 1720 ,(2020) , 10.1056/NEJMOA2002032
Anthony S. Fauci, H. Clifford Lane, Robert R. Redfield, Covid-19 — Navigating the Uncharted The New England Journal of Medicine. ,vol. 382, pp. 1268- 1269 ,(2020) , 10.1056/NEJME2002387
Xueting Yao, Fei Ye, Miao Zhang, Cheng Cui, Baoying Huang, Peihua Niu, Xu Liu, Li Zhao, Erdan Dong, Chunli Song, Siyan Zhan, Roujian Lu, Haiyan Li, Wenjie Tan, Dongyang Liu, In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. ,vol. 71, pp. 732- 739 ,(2020) , 10.1093/CID/CIAA237
Philippe Colson, Jean-Marc Rolain, Jean-Christophe Lagier, Philippe Brouqui, Didier Raoult, Chloroquine and Hydroxychloroquine as Available Weapons to Fight COVID-19 International Journal of Antimicrobial Agents. ,vol. 55, pp. 105932- ,(2020) , 10.1016/J.IJANTIMICAG.2020.105932
Jia Liu, Ruiyuan Cao, Mingyue Xu, Xi Wang, Huanyu Zhang, Hengrui Hu, Yufeng Li, Zhihong Hu, Wu Zhong, Manli Wang, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Cell discovery. ,vol. 6, pp. 16- 16 ,(2020) , 10.1038/S41421-020-0156-0
Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, Van Thuan Hoang, Line Meddeb, Morgane Mailhe, Barbara Doudier, Johan Courjon, Valérie Giordanengo, Vera Esteves Vieira, Hervé Tissot Dupont, Stéphane Honoré, Philippe Colson, Eric Chabrière, Bernard La Scola, Jean-Marc Rolain, Philippe Brouqui, Didier Raoult, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. ,vol. 56, pp. 105949- 105949 ,(2020) , 10.1016/J.IJANTIMICAG.2020.105949